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ABSTRACT Analysis of the genetic changes in human
tumors is often problematical because of the presence of
normal stroma and the limited availability of pure tumor
DNA. However, large amounts of highly reproducible ‘‘repre-
sentations’’ of tumor and normal genomes can be made by
PCR from nanogram amounts of restriction endonuclease
cleaved DNA that has been ligated to oligonucleotide adaptors.
We show here that representations are useful for many types
of genetic analyses, including measuring relative gene copy
number, loss of heterozygosity, and comparative genomic
hybridization. Representations may be prepared even from
sorted nuclei from fixed and archived tumor biopsies.
Analysis of the genetic changes in human tumors is often
problematical because of the presence of normal stroma.
Although either microdissection or flow cytometry can pro-
duce small samples highly enriched for tumor cells or nuclei,
the extracted DNA is of insufficient quantity for most uses.
Nevertheless, we have successfully performed a complex pro-
tocol, representational difference analysis (RDA), on such
small samples. RDA is a subtractive DNA hybridization tech-
nique that discovers the differences between paired normal
and tumor genomes (1). The first step of RDA is the prepa-
ration of ‘‘representations,’’ which are highly reproducible
reformattings and amplifications of DNA populations. Typi-
cally, a representation is a set of restriction endonuclease
fragments of a limited size range amplified by PCR. As much
as 100 mg of DNA can be prepared from as little as 3 ng of
DNA ('1 3 103 cells).
In RDA, a representation with much lower complexity than
the starting population is needed to enable a subtractive
hybridization step to proceed effectively. Such low complexity
representations (LCRs) do not ‘‘capture’’ enough (typically,
#7%) of the genome to be useful for many of the more
common types of analyses. However, we demonstrate here that
high complexity representations (HCRs) can provide ample
amounts of DNA in a sufficiently reproducible manner suit-
able for most conventional studies. We demonstrate one type
of HCR that captures '70% of the genome and illustrate its
use for determining gene copy number, deletion mapping, loss
of heterozygosity (LOH), and comparative genomic hybrid-
ization (CGH). HCRs may be a generally useful means of
‘‘immortalizing’’ and archiving DNA for later analysis from
nonrenewable sources.
MATERIALS AND METHODS
Materials. Restriction endonucleases as well as T4 DNA
ligase, T4 DNA polymerase, and T4 polynucleotide kinase
were supplied by New England Biolabs. AmpliTaq was sup-
plied by Perkin–Elmer. Oligonucleotide adaptors RBgl-12 and
RBgl-24 [as used in Lisitsyn et al. (1)], oligonucleotides used
for PCR of World-Wide Web probes, and tetranucleotide
repeat D17S695 were synthesized by BioSynthesis (Lewisville,
TX). Genescreen Plus was purchased from DuPont. Radioac-
tive nucleotides, rediprime labeling kit, dNTPs, and hyperfilm
were purchased from Amersham Pharmacia Biotech (Uppsala,
Sweden). Cell lines used were obtained through American
Type Culture Collection, grown in culture, and DNA-
prepared. Normal human placenta DNA was obtained from
CLONTECH. Oligonucleotides and probes for use with the
Applied Biosystems 7700 Sequence Detector were synthesized
by Applied Biosystems. Nusieve agarose gels used for analysis
of PCR products were purchased from FMC. World-Wide
Web probe sequences were downloaded from the Massachu-
setts Institute of Technology human genome sequencing da-
tabase (http:yywww-genome.wi.mit.eduy).
Production of Representations. Genomic DNA (3–10 ng)
was digested by the desired restriction endonucleases (DpnII
and BglII) under conditions suggested by the supplier. The
digest was purified by phenol extraction and then precipitated
in the presence of 10 mg of tRNA. The digested DNA was
resuspended by the addition of 444 pmol of each adaptor
(RBgl24 and RBgl12), T4 DNA ligase buffer (diluted to 13,
provided with enzyme), and water to bring the volume to 30 ml.
The reaction was placed in a 55°C heat block, and the
temperature was decreased slowly to 15°C by placing the heat
block at 4°C (for '1 hr). On reaching 15°C, the RBgl24
adaptor was ligated by the addition of 400 units of T4 DNA
ligase and by incubation at 15°C for 12–18 hr. The ligated
material was divided into two tubes, and the following was
added: 80 ml of 53 PCR buffer [335 mM TriszHCl, pH 8.8y20
mM MgCl2y80 mM (NH4)2SO4y50 mM b-mercaptoethanoly
0.5 mg/ml of BSA], 29-deoxynucleoside 59-triphosphates to a
final concentration of 0.32 mM, RBgl24 adaptor to a final
concentration of 0.6 mM, and H2O to bring the volume to 400
ml. Each reaction was overlaid with 100 ml of mineral oil. The
reaction was placed in a thermal cycler preheated at 72°C, and
15 units of AmpliTaq was added to the tubes. The thermal
cycler was set to continue at 72°C for 5 min to allow for filling
in the 39 ends of the ligated molecules. This step was followed
by 20 cycles lasting 1 min at 95°C and 3 min at 72°C, with an
additional extension of 10 min at 72°C after the last cycle. The
PCR was divided into two tubes (now a total of four tubes), and
the following reagents were added: 40 ml 53 PCR buffer (as
above), dNTP to a final concentration of 0.32 mM, RBgl24
adaptor to a final concentration of 0.6 mM, water to bring the
volume to 400 ml, and 100 ml of mineral oil. The tubes then
were amplified for an additional five cycles with extension
according to the above conditions. The reactions were purified
by phenol-chloroform and then precipitated by the addition of
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1y10th the reaction volume of sodium acetate (3M pH 5.2) and
by the addition of one reaction volume of isopropanol.
PTEN Tumor Suppressor Lori Genomic Sequencing. Bac-
terial artificial chromosome DNA was purified by detergent
lysis and polyethylene glycol precipitation. DNA (5 mg) was
sheared and then repaired by using T4 DNA polymerase.
Fragments in the range of 1.5–2 kb were isolated by gel
fractionation and inserted into M13 by ligation. Sequencing
reactions were done by using dye primer chemistry that uses
energy transfer primers (2) and thermosequenase polymerase
(3). Reactions were run on an Applied Biosystems 377 se-
quencer for 6- to 8-hr sequence runs for analysis. Base calling
was carried out by using the program PHRED (P. Green,
University of Washington). The collection of initial data was
assembled into a contig by using the automated assembly
program PHRAP (P. Green). The database generated was
converted to XGAP format and edited by using XGAP (4, 5).
After completion of '6-fold coverage, the finishing process
was carried out by using the program FINISH (G. Marth,
Genome Sequencing Center at Washington University) to fill
gaps in the contig.
Southern Blotting. Normal DNA from a tumor cell line or
representations derived from sorted nuclei were digested with
either DpnII or BglII. Digested genomic DNA (5.0 mg),
digested HCR (5.0 mg) , or digested LCR (0.5 mg) was loaded
on a 1.5% agarose gel. The gel was transferred to Genescreen
Plus after electrophoresis was completed. After transfer, the
blot was hybridized in GIBCO prehybridization solution at
67°C for 2 hr. The probe was produced by random priming with
the rediprime kit in the presence of 32PadCTP. After 12–18 hr
of hybridization, the blots were washed with standard saline
phosphateyEDTA buffer as described (6). The blots were used
for producing either auto-radiograms andyor phosphorimages.
LOH Analysis. LOH was assessed by using the tetranucle-
otide repeat marker D17S695 (listed as UT269 in the National
Center for Biotechnology Information Web Site http:yy
www.ncbi.nlm.nih.govyEntrezynucleotide.html), which maps
to the 17p13 region of the human genome and has been used
to determine the state of LOH at the p53 locus (7, 8). The
reverse primer was labeled by phosphorylation in the presence
of 32PgATP as described (7, 8). The labeled reverse primer in
combination with both forward and reverse primers was used
for PCR by using 50 ng of HCR as DNA template. PCRs were
performed as described in the National Center for Biotech-
nology Information Web Site, and gel electrophoresis was
performed as described (7, 8).
CGH. CGH was performed according to standard proce-
dure (9) by using HCR DNAs and genomic DNAs prepared
from BT474 and MCF7 as target and normal female human
lymphocyte as the reference. The genomic and HCR DNA
samples were labeled by nick-translation with fluorescein
isothiocyanate–12-dUTP and Texas Red 5-dUTP to produce
DNA fragments ranging in size between 500 and 2,000 bp.
Quantitative PCR. Primer and probe sequences were pro-
duced according to the Applied Biosystems software PRIMER
EXPRESS. These primers and probes were used in a PCR that
was placed in the Applied Biosystems 7700 Sequence Detector
and amplified as described (10, 11). Samples used were HCRs
produced from DNA derived from nuclei of sorted primary
tumor biopsies. After the PCR, the data of fluorescence
corresponding to cycle number were downloaded from the
Applied Biosystems 7700 Sequence Detector to Microsoft
EXCEL and analyzed to give the graphs shown later.
RESULTS
The Basic Method. DNA from samples, usually paired tumor
cells or nuclei and normal cells or nuclei, were processed in
parallel to prepare representations. DNA was cleaved with a
restriction endonuclease, such as DpnII or BglII, that is not
blocked by 5-methylcytosine, and double-stranded, cohesive,
adaptor oligonucleotides were ligated to the fragment ends.
The adaptors were not phosphorylated and therefore could not
be self-ligated to form interfering dimers. Because adaptors
can be ligated only to the 59 ends of the cleavage fragments, the
ligated product then was treated with DNA polymerase to fill
in the 39 ends, forming the primer binding site for the
subsequent PCR. Amplification was performed in stages, each
stage using the adaptor oligonucleotides as primers and pro-
ceeding for no more than 20 rounds per stage. PCR does not
amplify all fragments equally well, and high molecular weight
fragments in particular are very poorly amplified. Thus, re-
striction endonucleases that cleave infrequently were used to
prepare LCRs, and enzymes that cleave frequently were used
to prepare HCRs (see Fig. 1). From 3 ng of starting material,
we could obtain 40 mg of total HCR from a total of 25 rounds.
We have not tested the usefulness of an HCR beyond a total
of 35 rounds.
Sampling the Complexity and Reproducibility of DpnII
Representations. We first sampled the reproducibility and
complexity of DpnII HCRs. We analyzed 14 different HCRs,
each made from 5 ng of DNA prepared from diploid nuclei
FIG. 1. Schematic comparison of LCR and HCR, illustrating the complexity reduction that occurs after cleavage with rare and frequent cutters,
respectively.
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separated from tumor biopsies by flow cytometry and each
amplified by PCR for 25 rounds. In our first sampling, we
designed pairs of PCR primers to detect Web Site sequence-
tagged sites. We picked sequence-tagged sites that were not
cleaved by DpnII and used primer pairs that amplified a single
band from total genomic DNA controls. Of these, 18 of 25
pairs (72%) were able to amplify the same molecular weight
fragment from each HCR, and 7 generally failed to amplify
from any HCR. Our results suggest that DpnII HCRs repro-
ducibly contain the same elements and '70% of the genome.
We performed a similar sampling with primer pairs derived
from the locus encoding the PTEN tumor suppressor gene, for
which we had the complete nucleotide sequence (unpublished
data). In this way, we were able to use primers derived from
DpnII fragments of known size. DpnII fragments were chosen
at random, and PCR primer pairs were designed for each.
Primer pairs (22 pairs) amplified single fragments by PCR
from control genomic DNAs. These pairs were used with the
same panel of 14 HCRs used above. Primer pairs (20 pairs)
amplified the expected fragment from all HCRs, and 2 pairs
failed to amplify from any. The fragments that were not in the
HCRs were the largest, 3,916 bp, and one of the smallest, 97
bp. Totaling all fragment lengths, 16,039 bp were included in
the HCRs, and 4,013 bp were excluded. Thus, assuming that
our initial selection of DpnII fragments was random, the HCRs
contained '75% of the PTEN region.
If DpnII cleavage is nearly complete during the preparation
of an HCR, we expect that no PCR primer pairs should readily
amplify from an HCR when the amplified sequence has an
internal DpnII site. To test this, we chose four primer pairs
from the PTEN locus that amplified a single fragment con-
taining a single internal DpnII site. All four pairs amplified
fragments from genomic DNA controls, and none amplified
detectable fragments from the 14 HCRs. We conclude that
HCRs prepared in parallel from samples processed in parallel
are reasonably reproducible and represent '70% of the hu-
man genome.
Measuring Gene Copy Number in HCRs. Tumor genomes
often contain either extra copies of sequences caused by gene
amplification or missing sequences caused by gene deletion. To
explore the usefulness of representations for measuring gene
copy number, we first compared Southern blots of genomic
DNA to blots of HCRs and LCRs. For this purpose, we used
human placental DNA as normal and prepared genomic DNA
from tumor cell lines amplified at c-erbB2 (BT-474) (12) or
c-myc (SK-BR-3) (13). HCRs and LCRs were made from cell
line or placental DNAs by using DpnII or BglII, respectively.
As probes we used small BglII fragments that we cloned from
P1s containing inserts from the designated loci. The blots,
shown in Fig. 2A, were quantitated by phosphorimaging. To
normalize for loading differences, the blots were stripped and
rehybridized with a single copy sequence probe. The normal-
ized ratios of signal from tumor and normal are tabulated in
Fig. 2B. The same relative copy number (tumor to normal) was
determined from blots of representations as was determined
from blots of genomic DNAs, indicating that there is a
quantitatively reproducible amplification of these test se-
quences during the preparation of either HCRs or LCRs
prepared in parallel from similar starting materials. Similar
results were obtained for the cyclin D locus (data not shown).
To explore the usefulness of HCRs for deletion mapping, we
blotted both genomic and HCR DNAs from tumor cell lines
for deletion at the 20p11 locus. This locus was discovered
initially by using RDA and subsequently was found to be
deleted frequently in gastrointestinal cancers (R.L., unpub-
lished data). Fig. 2C illustrates that the probe hybridized to
sequences in the HCRs when and only when it hybridized to
sequences in the respective genomic DNA. An unrelated probe
detects sequences present in all genomic samples and their
representations.
We tested the value of the HCRs made from limited
amounts of DNA for quantitation of copy number. HCRs
prepared from aneuploid and diploid nuclei sorted from
several breast cancer biopsies were blotted for c-erbB2. Fig. 3A
illustrates that c-erbB2 is amplified in the HCRs made from the
aneuploid nuclei of some biopsy samples. Fig. 3B shows the
blots with an unrelated probe. We obtained confirmation of
the validity of the c-erbB2 amplifications by demonstrating
that probes adjacent to but distinct from the c-erbB2 probe also
were amplified in the same samples (M.N., unpublished re-
sults).
FIG. 2. Analysis of copy number using representations (Rep) and
genomic DNA (Gen) for c-erbB2 and c-myc. (A) Southern blot
comparing tumor cell lines (T) to normal (N) cell lines. DpnII was used
to prepare HCRs (DpnII), and BglII was used to prepare LCRs (BglII).
As a reference, free probe also was run alongside the samples (probe).
The hybridization probes were derived from small BglII fragments
isolated from P1 clones specific for each locus respectively. (B)
Quantitation of the Southern blot. Rep, representation; Gen, genomic
DNA; DpnII, either DpnII HCR or DpnII digest of genomic DNA;
BglII, either BglII HCR or BglII digest of genomic DNA. Blots in A
were stripped and reprobed with a single copy probe to analyze loading
differences (data not shown). Phosphorimage analysis of this probe
was used to normalize the amplification differences. After this anal-
ysis, the resulting intensity of tumor was divided by the intensity of
normal to give the fold amplification displayed. (C) Deletion mapping
using HCRs and the deletion mapping of seven tumor cell lines
comparing blots of HCRs (HCR) with blots of the corresponding
genomic DNA (Genomic), each designated 1–7. The probe used for
hybridization is from the human genomic region 20p11 (HCR). The
Genomic panel shows the same DNAs blotted with an unrelated probe.
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Finally, we tested some of the same samples by quantitative
PCR. For this purpose, we used the dual-labeled fluorogenic
hybridization probes and the Applied Biosystems 7700 Se-
quence Detector (10, 11) to compare HCR DNAs prepared
from aneuploid and diploid nuclei pairs. The results, shown in
Fig. 4, indicate that differences in copy number were detected
by probes for the c-erbB2 oncogene and the p16 tumor
suppressor. On the other hand, no differences in copy number
were detected by probes from an uninvolved region on chro-
mosome 3. The curve of amplification of the c-erbB2 fragment
arises four cycles sooner in one aneuploid HCR than it does in
the paired diploid HCR, indicating a higher copy number for
c-erbB2 ('16-fold higher in the aneuploid HCR sample). The
curve for the aneuploid HCR deleted for p16 arises three
cycles later than the paired diploid HCR (approximately
one-eighth as much in the aneuploid HCR), probably reflect-
ing '10% contamination of the aneuploid nuclei with diploid
nuclei after sorting. These results were confirmed by Southern
blotting (data not shown). One tumorynormal pair showed a
shift of a single cycle for primer pairs detecting the p16 gene,
which might reflect loss of a single allele in the tumor or
experimental error.
Detection of LOH in HCRs. LOH is a common lesion found
in cancer cells and may be indicative of genomic instability
andyor the loss of function of a specific tumor suppressor gene
(14–17). The detection of LOH often is obscured by the
presence of normal stroma; hence, we tested whether HCRs
prepared from minute amounts of samples highly enriched for
tumor nuclei could be used for LOH analysis. PCR primers
that amplify microsatellites and detect fragment length poly-
morphisms are used frequently for LOH mapping, and we
chose to examine a primer pair that amplifies a highly poly-
morphic tetranucleotide repeat near the p53 locus (7, 8).
In preliminary experiments, we established that these PCR
primers detected the same allele pattern in both genomic and
HCR DNAs prepared from cell lines. Next, we examined 12
pairs of HCRs prepared from aneuploid and diploid nuclei.
LOH at this locus was detected clearly in 9 of 10 informative
pairs (see Fig. 5 for representative cases), which is greater than
the reported proportion of LOH at this locus in breast cancer
(50%) (14, 18, 19) but may reflect the selection of the highly
aneuploid tumors that we sorted andyor the purity of our
samples.
Comparative Genome Hybridization with HCRs. CGH is a
powerful tool for analyzing the global genomic changes of
tumors (20–25). It has been reported that chromosome paint-
FIG. 3. Comparison of HCRs from primary tumor biopsies by
Southern blotting. (A) HCRs from the designated tumor biopsies
(denoted by an identification number preceded by BBR) were pre-
pared from diploid (Dpl) and aneuploid (Anu) nuclei and compared
by Southern blot analysis. The c-erbB2 probe was the same as that used
in Fig. 2. (B) The same DNAs blotted with an unrelated probe.
FIG. 4. Quanitative PCR analysis of HCRs. Diploid (black) and aneuploid (gray) HCRs derived from sorted primary tumor biopsies were used
as template for quanitative PCR analysis. Probes from several genomic loci (FHIT, p16, and c-erbB2) were used to determine copy number in three
primary tumor pair HCRs (BBR44, BBR49, and CHTN5). The data from the Applied Biosystems 7700 Sequence Detector was analyzed with
Microsoft EXCEL to produce the graphs shown. (x axis, the cycle number during the reaction; y axis, the fluorescence detected.)
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ing could be performed with representations produced from
each chromosome (26). We therefore tested whether CGH
could be performed with HCRs. For this experiment, we chose
to examine tumor cell lines so that we could directly compare
CGH performed with genomic DNA with CGH performed
with HCR. Little difference between HCR and genomic DNA
could be discerned with either of the two cell lines examined,
BT-474 and MCF7. Fig. 6 shows a sample of the chromosomal
scanning profiles obtained with each DNA source.
DISCUSSION
The idea of capturing essential features of the genome as a
PCR product is not new. In 1989, Kinzler and Vogelstein (27)
described ‘‘whole genome’’ PCRs to select for DNA sequences
that were binding sites for DNA binding proteins. Their
method was used in 1995 (28) for the same purpose. In the
experiments from 1989, PCR adaptors were blunt-end ligated
to the cleavage fragments of total genomic DNA. The useful-
ness of the resulting PCR products for genomic analysis was
not explored; nor was its efficiency explored when starting with
tiny amounts of material. An alternate approach to whole
genome PCR is to use random priming with degenerate
oligonucleotides (29–33). This method can produce large
amounts of DNA starting from very minute amounts of
sample, but the complexity of the DNA produced, the repro-
ducibility of the representation, and the loss of natural restric-
tion sites at the ends of the amplified material make the
usefulness of this method somewhat limited. Restriction en-
donuclease-based representations have major advantages:
Their complexity can be regulated by the choice of restriction
enzyme; they can be readily reamplified; they can be analyzed
by Southern blotting; and they are highly reproducible.
In this report, we have explored the uses of HCRs, including
quantitative assessment of copy number, LOH, and CGH. All
of these analytical methods require a high level of reproduc-
ibility in the representation. To achieve this level of reproduc-
ibility, we have prepared paired samples of HCRs from the
same amount of starting material, used genomic DNAs ex-
tracted in the same manner, and performed PCR at the same
time, under the same conditions, and in the same thermal
cycler.
In principle, HCRs can be prepared from normal and tumor
tissue stored as fixed, paraffin-embedded, archived biopsies,
which would extend greatly the usefulness of such samples. We
have made HCRs from DNAs extracted from pairs of aneu-
ploid and diploid nuclei sorted from such sources (R.L.,
unpublished data). More rounds of PCR are required to obtain
workable amounts of DNA, and HCRs from DNA extracted
from fixed specimens have a markedly lower size distribution
than HCRs prepared from fresh sources. Moreover, there is
enormous variability between the HCRs from different spec-
imens, reflected as varying size distributions. This diversity is
probably caused by the variation in the quality of the DNA that
can be extracted from specimens fixed and stored under
different conditions (19, 34–36). Despite the variability be-
tween specimens, we found that the HCRs prepared from
aneuploid and diploid nuclei from the same fixed specimen are
similar to each other. Indeed, we have found that HCRs
prepared from sorted nuclei of fixed specimens are useful for
CGH (unpublished observations). These results suggest that
normal and tumor HCRs will be useful even when prepared for
analysis from microdissected specimens.
Both HCR and LCR render paired tumor and normal DNAs
from minute specimens in a stable format that can be analyzed
or further amplified at a later date. We have emphasized the
usefulness of HCRs for gene copy, LOH, and global genomic
analysis of tumor specimens. Most probes, chosen at random,
will be present in an HCR but will not be present in the LCRs.
However, precisely because LCRs are of lower complexity,
FIG. 5. Using HCRs for LOH analysis. LOH analysis was carried
out on HCRs derived from sorted primary tumor biopsies. Dpl, diploid
HCR; Anu, aneuploid HCR. The tumors are labeled as either BBR,
CHTN, or NSBR followed by an identification number. The primers
used in the reaction amplify a tetranucleotide repeat within the p53
locus. A mixed population of normal DNAs was used as a positive
control. (1Gen, normal genomic DNA used as template; 1HCR,
HCR produced from this normal DNA used as template. 2, reaction
in which no template was added.)
FIG. 6. CGH analysis using HCRs. Shown are two representative chromosome spreads (Ch 1, and Ch17) comparing the genomic (Gen) with
the HCR for two different cell lines, BT474, and MCF7. Deviation from the dashed line represents genomic change, a peak represents gain in copy
number, and a trough represents loss of copy number. Underneath the profiles is an idiogram of each chromosome as a reference.
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hybridization-based assays that depend on completeness of
hybridization are easier to perform. This ease is apparent in
blotting analysis of LCRs. For the same reason, some global
genomic analyses, such as microchip array analysis (37–40) or
CGH (20–25), that depend on hybridization kinetics should be
facilitated by the use of LCRs because reannealing times
should be reduced and signal-to-noise ratios enhanced.
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